How do you figure that recent financing is counter to all bulish bias about CD47/TRIL?
In retrospect they made a huge financing mistake last year by not raising 30 million at 15 which would have been a 20% dilution.
Now 7 months later they are forced to dilute greater because of the increased trial expenses. Why would anyone give them money without vetting the technology/results which typical shareholder does not get to see?
Can you cite any negative CD47 studies that support your theory?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.